Show simple item record

dc.contributor.authorAlgotar, A.M.
dc.contributor.authorKumar, R.
dc.contributor.authorBabiker, H.M.
dc.contributor.authorDougherty, S.T.
dc.contributor.authorHsu, C.H.
dc.contributor.authorChow, H.-H.
dc.contributor.authorSmith, T.E.
dc.contributor.authorMarrero, D.G.
dc.contributor.authorCourneya, K.S.
dc.contributor.authorAbraham, I.
dc.contributor.authorLigibel, J.A.
dc.contributor.authorThomson, C.A.
dc.date.accessioned2021-06-05T02:34:52Z
dc.date.available2021-06-05T02:34:52Z
dc.date.issued2021
dc.identifier.citationAlgotar, A. M., Kumar, R., Babiker, H. M., Dougherty, S. T., Hsu, C. H., Chow, H. H., ... & Thomson, C. A. (2021). Protocol for a feasibility and early efficacy study of the Comprehensive Lifestyle Improvement Program for Prostate Cancer-2 (CLIPP2). Contemporary Clinical Trials Communications, 21, 100701.
dc.identifier.issn2451-8654
dc.identifier.doi10.1016/j.conctc.2021.100701
dc.identifier.urihttp://hdl.handle.net/10150/659739
dc.description.abstractBackground: Although androgen deprivation therapy (ADT) for prostate cancer demonstrates improved overall and disease-free survival, it is associated with adverse effects such as obesity and metabolic syndrome that increase risk of cardiometabolic disease and diabetes type 2. ADT also leads to fatigue, depression and erectile dysfunction, which reduce quality of life (QoL). Lifestyle modification has shown promise in reducing obesity, metabolic syndrome and diabetes type 2 in other disease types. However, there is a paucity of data regarding the utility of lifestyle modification in men receiving ADT for prostate cancer. Methods: The primary aim of the Comprehensive Lifestyle Improvement Program for Prostate Cancer-2 (CLIPP2) is to test the feasibility of conducting a 24-week lifestyle modification intervention in men on ADT for prostate cancer. Additionally, it will also determine the effect of this intervention on weight loss, cardiometabolic markers (secondary aim and markers of interest: serum glucose, insulin resistance, hemoglobin A1C and lipid panel), and QoL (tertiary aim). The intervention will be delivered weekly via telephone for the first 10 weeks and bi-weekly for the remaining 14 weeks. Questionnaires and serum samples will be collected at baseline, week 12, and week 24. Anthropometric measurements will be collected at baseline, week 6, week 12, week 18 and week 24. Results: We hypothesize that the CLIPP2 intervention will produce a 7% weight loss that will result in improved markers associated with cardiometabolic disease and type 2 diabetes in the study population. Conclusion: Results will provide insight into the role of lifestyle modification in addressing ADT adverse effects as well as provide preliminary data to inform the development of future lifestyle interventions in this area. Trial registration: NCT04228055 Clinicaltrials. gov. © 2021
dc.language.isoen
dc.publisherElsevier Inc.
dc.rightsCopyright © 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAndrogen Deprivation Therapy
dc.subjectLifestyle Modification
dc.subjectProstate Cancer
dc.titleProtocol for a feasibility and early efficacy study of the Comprehensive Lifestyle Improvement Program for Prostate Cancer-2 (CLIPP2)
dc.typeArticle
dc.typetext
dc.contributor.departmentDepartment of Family and Community Medicine, University of Arizona
dc.contributor.departmentThe University of Arizona Cancer Center
dc.contributor.departmentDepartment of Hematology-Oncology, University of Arizona
dc.contributor.departmentDepartment of Radiation Oncology, University of Arizona
dc.contributor.departmentDepartment of Epidemiology and Biostatistics, Mel and Enid College of Public Health, University of Arizona
dc.contributor.departmentDepartment of Health Promotion Science, Mel and Enid College of Public Health, University of Arizona
dc.contributor.departmentCollege of Pharmacy, University of Arizona
dc.identifier.journalContemporary Clinical Trials Communications
dc.description.noteOpen access journal
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.
dc.eprint.versionFinal published version
dc.source.journaltitleContemporary Clinical Trials Communications
refterms.dateFOA2021-06-05T02:34:52Z


Files in this item

Thumbnail
Name:
1-s2.0-S2451865421000041-main.pdf
Size:
2.663Mb
Format:
PDF
Description:
Final Published Version

This item appears in the following Collection(s)

Show simple item record

Copyright © 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Except where otherwise noted, this item's license is described as Copyright © 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).